,address1,address2,city,state,zip,country,phone,website,industry,sector,longBusinessSummary,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,7 Eden Park Drive,Level 5,Macquarie Park,NSW,2113,Australia,61 2 8935 9629,https://www.oncosil.com.au,Medical Devices,Healthcare,"OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.","{'maxAge': 1, 'name': 'Mr. Nigel  Lange', 'title': 'CEO, MD & Director', 'fiscalYear': 2023, 'totalPay': 388259, 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.011,0.01,0.01,0.01,0.011,0.01,0.01,0.01,0.0,0.444819,-1.0,2000000,2000000,2746650,1873135,1873135,0.01,0.011,0,0,21734300,0.009,0.053,14.811223,0.01135,0.02254404,0.0,0.0,AUD,10535387,0.0,1480438485,1975840000,0.17437,0.024519999,0.005,2.0,1688083200,1719705600,1688083200,-11342926,-0.01,-0.01,7.18,-0.931,ASX,EQUITY,OSL.AX,OSL.AX,ONCOSIL FPO,OncoSil Medical Limited,1124064000,Australia/Sydney,AEST,36000000,0.01,3.0,hold,9393832,0.005,-11315261,170808,6.806,7.16,1467421,1.729,0.001,-0.57730997,-1.07805,-121353,-7143765,-11315634,0.448,-0.08270001,0.0,-7.72477,AUD,
1,7 Eden Park Drive,Level 5,Macquarie Park,NSW,2113,Australia,61 2 8935 9629,https://www.oncosil.com.au,Medical Devices,Healthcare,"OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.","{'maxAge': 1, 'name': 'Mr. Christian  Dal Cin', 'title': 'CFO & Company Sec.', 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.011,0.01,0.01,0.01,0.011,0.01,0.01,0.01,0.0,0.444819,-1.0,2000000,2000000,2746650,1873135,1873135,0.01,0.011,0,0,21734300,0.009,0.053,14.811223,0.01135,0.02254404,0.0,0.0,AUD,10535387,0.0,1480438485,1975840000,0.17437,0.024519999,0.005,2.0,1688083200,1719705600,1688083200,-11342926,-0.01,-0.01,7.18,-0.931,ASX,EQUITY,OSL.AX,OSL.AX,ONCOSIL FPO,OncoSil Medical Limited,1124064000,Australia/Sydney,AEST,36000000,0.01,3.0,hold,9393832,0.005,-11315261,170808,6.806,7.16,1467421,1.729,0.001,-0.57730997,-1.07805,-121353,-7143765,-11315634,0.448,-0.08270001,0.0,-7.72477,AUD,
2,7 Eden Park Drive,Level 5,Macquarie Park,NSW,2113,Australia,61 2 8935 9629,https://www.oncosil.com.au,Medical Devices,Healthcare,"OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.","{'maxAge': 1, 'name': 'Dr. Ralph  Peters', 'title': 'Chief Medical Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.011,0.01,0.01,0.01,0.011,0.01,0.01,0.01,0.0,0.444819,-1.0,2000000,2000000,2746650,1873135,1873135,0.01,0.011,0,0,21734300,0.009,0.053,14.811223,0.01135,0.02254404,0.0,0.0,AUD,10535387,0.0,1480438485,1975840000,0.17437,0.024519999,0.005,2.0,1688083200,1719705600,1688083200,-11342926,-0.01,-0.01,7.18,-0.931,ASX,EQUITY,OSL.AX,OSL.AX,ONCOSIL FPO,OncoSil Medical Limited,1124064000,Australia/Sydney,AEST,36000000,0.01,3.0,hold,9393832,0.005,-11315261,170808,6.806,7.16,1467421,1.729,0.001,-0.57730997,-1.07805,-121353,-7143765,-11315634,0.448,-0.08270001,0.0,-7.72477,AUD,
3,7 Eden Park Drive,Level 5,Macquarie Park,NSW,2113,Australia,61 2 8935 9629,https://www.oncosil.com.au,Medical Devices,Healthcare,"OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.","{'maxAge': 1, 'name': 'Mr. David  Turner', 'title': 'Head of Medical Affairs', 'exercisedValue': 0, 'unexercisedValue': 0}",1703980800,86400,4,0.011,0.01,0.01,0.01,0.011,0.01,0.01,0.01,0.0,0.444819,-1.0,2000000,2000000,2746650,1873135,1873135,0.01,0.011,0,0,21734300,0.009,0.053,14.811223,0.01135,0.02254404,0.0,0.0,AUD,10535387,0.0,1480438485,1975840000,0.17437,0.024519999,0.005,2.0,1688083200,1719705600,1688083200,-11342926,-0.01,-0.01,7.18,-0.931,ASX,EQUITY,OSL.AX,OSL.AX,ONCOSIL FPO,OncoSil Medical Limited,1124064000,Australia/Sydney,AEST,36000000,0.01,3.0,hold,9393832,0.005,-11315261,170808,6.806,7.16,1467421,1.729,0.001,-0.57730997,-1.07805,-121353,-7143765,-11315634,0.448,-0.08270001,0.0,-7.72477,AUD,
